Efficacy and safety of immunosuppressive therapy in the treatment of seronegative hepatitis associated aplastic anemia
Hai-Fei Chen,* Bin-Xian Xu, Hong-Shi Shen,* Zheng-Yang Li, Ling-Juan Jin, Jie-Qing Tang, Jing Wang, Jing-Jing Zhu, Long-Mei Qin, Qing-Ya Cui, Yong-Ya Ren, Tian-Qin Wu Department of hematology, 100th hospital of People’s Liberation Army, Suzhou, Jiangsu province, The People&rs...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2014-09-01
|
| Series: | Drug Design, Development and Therapy |
| Online Access: | http://www.dovepress.com/efficacy-and-safety-of-immunosuppressive-therapy-in-the-treatment-of-s-peer-reviewed-article-DDDT |
| _version_ | 1819044012340805632 |
|---|---|
| author | Chen HF Xu BX Shen HS Li ZY Jin LJ Tang JQ Wang J Zhu JJ Qin LM Cui QY Ren YY Wu TQ |
| author_facet | Chen HF Xu BX Shen HS Li ZY Jin LJ Tang JQ Wang J Zhu JJ Qin LM Cui QY Ren YY Wu TQ |
| author_sort | Chen HF |
| collection | DOAJ |
| description | Hai-Fei Chen,* Bin-Xian Xu, Hong-Shi Shen,* Zheng-Yang Li, Ling-Juan Jin, Jie-Qing Tang, Jing Wang, Jing-Jing Zhu, Long-Mei Qin, Qing-Ya Cui, Yong-Ya Ren, Tian-Qin Wu Department of hematology, 100th hospital of People’s Liberation Army, Suzhou, Jiangsu province, The People’s Republic of China *These authors have contributed equally to this paper Objective: To investigate the clinical characteristics of seronegative hepatitis-associated aplastic anemia (AA) (SNHAA) and hepatitis B virus (HBV) infection complicating AA (HBVAA), and thereby compare the efficacy of immunosuppressive therapy (IST).Methods: An analysis was conducted on the clinical data of ten patients with SNHAA out of 332 cases of AA from our center at AA diagnosis, and on the efficacy of IST. This was compared to 22 cases of HBVAA at AA onset as well as the associated IST outcomes.Results: Nine patients with SNHAA developed severe aplastic anemia, with a median age of 18 years. After IST, six (60%) of the SNHAA patients achieved complete remission and two achieved partial remission. The patients with HBVAA had a total response rate of 82.3%. The disease recurred in two HBVAA patients. No statistically significant differences were observed in response rate, mortality, and recurrence rate between both groups. As compared with HBVAA, patients with SNHAA had a shorter interval from the acute episode of hepatitis to AA onset (4 months versus 92 months, P=0.00), a quicker response to IST (2.5 months versus 4.5 months, P=0.018), a lower proportion of bone marrow hematopoietic tissues (20.6% versus 23.6%, P=0.03), and lower white blood cell and absolute neutrophil count (0.8×109/L versus 1.23×109/L and 0.26×109/L versus 0.58×109/L, P=0.026 and P=0.0009, respectively). No significant liver damage or hepatitis B fulminant infection was observed in either group during the follow-up. Conclusion: The prevalence of SNHAA is 3.01%. SNHAA often presents as severe AA and responds to IST quickly. Neither hepatitis prior to AA nor AA complicating HBV infection have been shown to influence the early efficacy of IST and adverse events, and HBV may not be the causative agent of AA. Keywords: hepatitis-associated aplastic anemia, hepatitis B infection, liver injury |
| first_indexed | 2024-12-21T10:05:54Z |
| format | Article |
| id | doaj.art-621ce6b48a2943399c9da79a0d7eb3e1 |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-12-21T10:05:54Z |
| publishDate | 2014-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-621ce6b48a2943399c9da79a0d7eb3e12022-12-21T19:07:50ZengDove Medical PressDrug Design, Development and Therapy1177-88812014-09-012014default1299130518245Efficacy and safety of immunosuppressive therapy in the treatment of seronegative hepatitis associated aplastic anemiaChen HFXu BXShen HSLi ZYJin LJTang JQWang JZhu JJQin LMCui QYRen YYWu TQHai-Fei Chen,* Bin-Xian Xu, Hong-Shi Shen,* Zheng-Yang Li, Ling-Juan Jin, Jie-Qing Tang, Jing Wang, Jing-Jing Zhu, Long-Mei Qin, Qing-Ya Cui, Yong-Ya Ren, Tian-Qin Wu Department of hematology, 100th hospital of People’s Liberation Army, Suzhou, Jiangsu province, The People’s Republic of China *These authors have contributed equally to this paper Objective: To investigate the clinical characteristics of seronegative hepatitis-associated aplastic anemia (AA) (SNHAA) and hepatitis B virus (HBV) infection complicating AA (HBVAA), and thereby compare the efficacy of immunosuppressive therapy (IST).Methods: An analysis was conducted on the clinical data of ten patients with SNHAA out of 332 cases of AA from our center at AA diagnosis, and on the efficacy of IST. This was compared to 22 cases of HBVAA at AA onset as well as the associated IST outcomes.Results: Nine patients with SNHAA developed severe aplastic anemia, with a median age of 18 years. After IST, six (60%) of the SNHAA patients achieved complete remission and two achieved partial remission. The patients with HBVAA had a total response rate of 82.3%. The disease recurred in two HBVAA patients. No statistically significant differences were observed in response rate, mortality, and recurrence rate between both groups. As compared with HBVAA, patients with SNHAA had a shorter interval from the acute episode of hepatitis to AA onset (4 months versus 92 months, P=0.00), a quicker response to IST (2.5 months versus 4.5 months, P=0.018), a lower proportion of bone marrow hematopoietic tissues (20.6% versus 23.6%, P=0.03), and lower white blood cell and absolute neutrophil count (0.8×109/L versus 1.23×109/L and 0.26×109/L versus 0.58×109/L, P=0.026 and P=0.0009, respectively). No significant liver damage or hepatitis B fulminant infection was observed in either group during the follow-up. Conclusion: The prevalence of SNHAA is 3.01%. SNHAA often presents as severe AA and responds to IST quickly. Neither hepatitis prior to AA nor AA complicating HBV infection have been shown to influence the early efficacy of IST and adverse events, and HBV may not be the causative agent of AA. Keywords: hepatitis-associated aplastic anemia, hepatitis B infection, liver injuryhttp://www.dovepress.com/efficacy-and-safety-of-immunosuppressive-therapy-in-the-treatment-of-s-peer-reviewed-article-DDDT |
| spellingShingle | Chen HF Xu BX Shen HS Li ZY Jin LJ Tang JQ Wang J Zhu JJ Qin LM Cui QY Ren YY Wu TQ Efficacy and safety of immunosuppressive therapy in the treatment of seronegative hepatitis associated aplastic anemia Drug Design, Development and Therapy |
| title | Efficacy and safety of immunosuppressive therapy in the treatment of seronegative hepatitis associated aplastic anemia |
| title_full | Efficacy and safety of immunosuppressive therapy in the treatment of seronegative hepatitis associated aplastic anemia |
| title_fullStr | Efficacy and safety of immunosuppressive therapy in the treatment of seronegative hepatitis associated aplastic anemia |
| title_full_unstemmed | Efficacy and safety of immunosuppressive therapy in the treatment of seronegative hepatitis associated aplastic anemia |
| title_short | Efficacy and safety of immunosuppressive therapy in the treatment of seronegative hepatitis associated aplastic anemia |
| title_sort | efficacy and safety of immunosuppressive therapy in the treatment of seronegative hepatitis associated aplastic anemia |
| url | http://www.dovepress.com/efficacy-and-safety-of-immunosuppressive-therapy-in-the-treatment-of-s-peer-reviewed-article-DDDT |
| work_keys_str_mv | AT chenhf efficacyandsafetyofimmunosuppressivetherapyinthetreatmentofseronegativehepatitisassociatedaplasticanemia AT xubx efficacyandsafetyofimmunosuppressivetherapyinthetreatmentofseronegativehepatitisassociatedaplasticanemia AT shenhs efficacyandsafetyofimmunosuppressivetherapyinthetreatmentofseronegativehepatitisassociatedaplasticanemia AT lizy efficacyandsafetyofimmunosuppressivetherapyinthetreatmentofseronegativehepatitisassociatedaplasticanemia AT jinlj efficacyandsafetyofimmunosuppressivetherapyinthetreatmentofseronegativehepatitisassociatedaplasticanemia AT tangjq efficacyandsafetyofimmunosuppressivetherapyinthetreatmentofseronegativehepatitisassociatedaplasticanemia AT wangj efficacyandsafetyofimmunosuppressivetherapyinthetreatmentofseronegativehepatitisassociatedaplasticanemia AT zhujj efficacyandsafetyofimmunosuppressivetherapyinthetreatmentofseronegativehepatitisassociatedaplasticanemia AT qinlm efficacyandsafetyofimmunosuppressivetherapyinthetreatmentofseronegativehepatitisassociatedaplasticanemia AT cuiqy efficacyandsafetyofimmunosuppressivetherapyinthetreatmentofseronegativehepatitisassociatedaplasticanemia AT renyy efficacyandsafetyofimmunosuppressivetherapyinthetreatmentofseronegativehepatitisassociatedaplasticanemia AT wutq efficacyandsafetyofimmunosuppressivetherapyinthetreatmentofseronegativehepatitisassociatedaplasticanemia |